170 related articles for article (PubMed ID: 27058664)
21. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
Domingo E; Niessen RC; Oliveira C; Alhopuro P; Moutinho C; Espín E; Armengol M; Sijmons RH; Kleibeuker JH; Seruca R; Aaltonen LA; Imai K; Yamamoto H; Schwartz S; Hofstra RM
Oncogene; 2005 Jun; 24(24):3995-8. PubMed ID: 15782118
[TBL] [Abstract][Full Text] [Related]
22. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
23. Timing of antitubulin therapy: does it matter?
Livingston RB
Cancer Invest; 2000; 18(8):804-5. PubMed ID: 11107452
[No Abstract] [Full Text] [Related]
24. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
Liu D; Liu Z; Condouris S; Xing M
J Clin Endocrinol Metab; 2007 Jun; 92(6):2264-71. PubMed ID: 17374713
[TBL] [Abstract][Full Text] [Related]
25. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
27. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents.
Dang LH; Bettegowda C; Agrawal N; Cheong I; Huso D; Frost P; Loganzo F; Greenberger L; Barkoczy J; Pettit GR; Smith AB; Gurulingappa H; Khan S; Parmigiani G; Kinzler KW; Zhou S; Vogelstein B
Cancer Biol Ther; 2004 Mar; 3(3):326-37. PubMed ID: 14739784
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
30. In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.
Yosef HK; Mavarani L; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
Anal Bioanal Chem; 2015 Nov; 407(27):8321-31. PubMed ID: 26168967
[TBL] [Abstract][Full Text] [Related]
31. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
32. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
33. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.
Samowitz WS; Albertsen H; Sweeney C; Herrick J; Caan BJ; Anderson KE; Wolff RK; Slattery ML
J Natl Cancer Inst; 2006 Dec; 98(23):1731-8. PubMed ID: 17148775
[TBL] [Abstract][Full Text] [Related]
34. The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.
Frouws MA; Reimers MS; Swets M; Bastiaannet E; Prinse B; van Eijk R; Lemmens VE; van Herk-Sukel MP; van Wezel T; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
PLoS One; 2017; 12(1):e0170775. PubMed ID: 28125730
[TBL] [Abstract][Full Text] [Related]
35. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
36. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA
J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810
[TBL] [Abstract][Full Text] [Related]
37. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549).
Jung M; Grunberg S; Timblin C; Buder-Hoffman S; Vacek P; Taatjes DJ; Mossman BT
Histochem Cell Biol; 2004 Feb; 121(2):115-21. PubMed ID: 14745558
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Pang VF; Liu RS; Lin WJ; Yang CS; Ting G
J Nucl Med; 2009 Dec; 50(12):2073-81. PubMed ID: 19949027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
